BioNTech Q4 2023 revenue dropped to €1.5bn as focus shifts to cancer drug development.

BioNTech, known for its Covid-19 vaccine with Pfizer, reported a drop in revenue and earnings for Q4 2023, as its focus shifts towards cancer drug development. The company's revenues for Q4 2023 were €1.5bn (equivalent to $1.6bn), significantly lower than 2022's figures. Full-year revenue for 2023 was €3.8bn, a sharp decline from 2022's revenue of €17.3bn. BioNTech is now aiming for its first oncology launch in 2026 and ten indication approvals by 2030.

March 20, 2024
14 Articles